Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

SpyGlass Pharma

Request full access

Developing novel technologies to improve the quality of life

Aliso Viejo, United StatesFounded 2019Biotech & Life Sciences

About SpyGlass Pharma

SpyGlass Pharma is a privately-held biotechnology company that operates in the ophthalmic industry. The company has developed a unique intraocular drug delivery platform designed to aid cataract surgeons in managing glaucoma patients. This platform is the world's first intraocular lens (IOL) mounted, controlled release drug delivery system capable of delivering multiple years of therapy.

The device is designed to be implanted during routine cataract surgery and releases a consistent daily dose of the drug bimatoprost, a medication used to treat glaucoma. The drug is released over a targeted period of three years, providing a long-term solution for patients. This method of drug delivery is independent of patient behavior, addressing the industry-wide issue of patient non-adherence to glaucoma medication, which can lead to disease progression and vision loss.

SpyGlass Pharma's business model revolves around providing this innovative solution to the millions of glaucoma patients who undergo cataract surgery each year. The company generates revenue by selling its drug delivery platform to healthcare providers.

Currently, the SpyGlass Pharma Drug Delivery Platform is undergoing a Phase I/II clinical trial. It's important to note that the platform has not yet been approved by the FDA.

Source: Dealroom company data

At a glance

Status
Operational
Employees
74
Open positions
10
Dealroom signal
94.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPOOther financing Feb 2026 $150M $842M Undisclosed ↗
SERIES DOther financing Jun 2025 $75M $450M NEA · Vensana Capital · Gilde Healthcare · RA Capital Management ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearEBITDAMargin
2026 —
2025 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

SpyGlass Pharma website traffic

Latest recorded traffic for SpyGlass Pharma is 5.7K monthly website visits, up 35.7% over the last three months. SpyGlass Pharma's team grew 23.3% over the past year.

Latest monthly visits5.7K 3-month web change+35.7% 1-year team growth+23.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

SpyGlass Pharma in the Aliso Viejo ecosystem

Live from Dealroom

The SpyGlass Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • NEA
  • Vensana Capital

Series B and later5 investors entered at this stage

Other known investors1 additional known investor

  • University of Colorado
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States98%
🇦🇺 Australia2%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about SpyGlass Pharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SpyGlass Pharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.